Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-19T01:12:12.724Z Has data issue: false hasContentIssue false
  • English
  • Français

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Published online by Cambridge University Press:  05 May 2021

Mohammad Aladawi ,
Mohamed Elfil Open the ORCID record for Mohamed Elfil [Opens in a new window] ,
Baha Abu-Esheh ,
Deaa Abu Jazar ,
Ahmad Armouti ,
Ahmed Bayoumi  and
Ezequiel Piccione
Mohammad Aladawi*
Affiliation:
Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA
Mohamed Elfil
Affiliation:
Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA
Baha Abu-Esheh
Affiliation:
Department of Neurology, Mercy Hospital, Oklahoma City, Oklahoma, USA
Deaa Abu Jazar
Affiliation:
Department of Neurology, University of Texas Medical Branch – Galveston, Galveston, Texas, USA
Ahmad Armouti
Affiliation:
Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA
Ahmed Bayoumi
Affiliation:
Department of Neurology, Yale University, New Haven, Connecticut, USA
Ezequiel Piccione
Affiliation:
Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA
*
Correspondence to: Mohammad Aladawi, MD, 988435 Nebraska Medical Center, Omaha, NE 68198-8435, USA. Email: Mohammad.aladawi@unmc.edu
Rights & Permissions [Opens in a new window]

Abstract:

Background:

In January 2020, the first case of Guillain Barre syndrome (GBS) due to COVID-19 was documented in China. GBS is known to be postinfectious following several types of infections. Although causality can only be proven through large epidemiological studies, we intended to study this association by a thorough review of the literature.

Methods:

We searched PubMed, EMBASE, and Google scholar and included all papers with English or Spanish full text and original data of patients with GBS and recent COVID infection. Variables of interest were demographics, diagnostic investigations, and the latency between arboviral and neurological symptoms. Further variables were pooled to identify GBS clinical and electrophysiological variants, used treatments, and outcomes. The certainty of GBS diagnosis was verified using Brighton criteria.

Results:

We identified a total of 109 GBS cases. Ninety-nine cases had confirmed COVID-19 infection with an average age of 56.07 years. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d. The predominant GBS clinical and electromyography variants were the classical sensorimotor GBS and acute demyelinating polyneuropathy respectively. Forty cases required intensive care, 33 cases required mechanical ventilation, and 6 cases were complicated by death.

Conclusions:

Studies on COVID-19-related GBS commonly reported sensorimotor demyelinating GBS with frequent facial palsy. The time between the onset of infectious and neurological symptoms suggests a postinfectious mechanism. Early diagnosis of GBS in COVID-19 patients is important as it might be associated with a severe disease course requiring intensive care and mechanical ventilation.

Résumé :

RÉSUMÉ :

Apparition du syndrome de Guillain-Barré à la suite d’une infection à la COVID-19 : une étude systématique.

Contexte :

C’est en janvier 2020 qu’on a documenté en Chine le premier cas de syndrome de Guillain-Barré (SGB) attribuable à une infection à la COVID-19. Le SGB est connu pour être post-infectieux et pour apparaître à la suite de plusieurs types d'infections. Bien qu’une réelle causalité puisse seulement être établie par l’entremise de vastes études épidémiologiques, nous nous sommes penchés sur cette association au moyen d’un examen approfondi de la littérature sur le sujet.

Méthodes :

Pour ce faire, nous avons interrogé les bases de données suivantes : PubMed, EMBASE et Google Scholar. À cet égard, nous avons inclus dans notre étude tous les articles complets rédigés en anglais ou en espagnol contenant des données originales à propos de patients atteints du SGB et ayant été infectés récemment à la COVID-19. Les variables qui nous ont le plus intéressés portaient sur leurs caractéristiques démographiques, sur les examens diagnostics qui avaient été effectués et sur la période de latence entre les symptômes dits « arboviraux » et ceux de nature neurologique. Davantage de variables ont été par la suite regroupées pour identifier les variantes cliniques et électro-physiologiques du SGB, les traitements utilisés et l’évolution de l’état de santé de ces patients. On a aussi pu valider la certitude d’un diagnostic de SGB à l’aide des critères de Brighton.

Résultats :

Au total, ce sont 109 cas de SGB que nous avons identifiés. De ce nombre, 99 étaient liés à des cas confirmés d’infection à la COVID-19, l’âge moyen des patients étant de 56,07 ans. La période moyenne de latence entre les premiers symptômes dits « arboviraux » et des manifestations neurologiques pour des cas confirmés d’infection à la COVID-19 a été de 12,2 jours. À noter que les variantes cliniques et électromyographiques prédominantes de la SGB ont relevé respectivement de la forme classique sensorimotrice et de la polyradiculonévrite inflammatoire démyélinisante associées à ce syndrome. Enfin, soulignons que 40 cas ont nécessité le recours aux soins intensifs, que 33 d’entre eux ont entraîné l’utilisation de la ventilation artificielle tandis que 6 autres se sont soldés par un décès.

Conclusion :

Il n’est pas rare que des études portant sur les liens entre le SGB et l’infection à la COVID-19 aient signalé un syndrome de type sensorimoteur démyélinisant avec de fréquentes manifestations de paralysie faciale. La période qui sépare une infection à la COVID-19 de l’apparition de symptômes neurologiques suggère ainsi un mécanisme post-infectieux. Un diagnostic précoce de SGB chez des patients infectés à la COVID-19 est donc important car un tel syndrome peut être associé à une évolution préoccupante de leur état de santé nécessitant des soins intensifs et une ventilation artificielle.

Keywords

Guillain Barre syndromeGBSMiller Fisher syndromeMFSSARS-CoV2COVID-19
Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 49 , Issue 1 , January 2022 , pp. 38 - 48
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Introduction

In December 2019, the COVID-19 epidemic emerged in Wuhan, China, causing global alterations not only in the field of healthcare, but also in all walks of life. The viral agent responsible for this clinical illness is described as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was documented that SARS-CoV-2 is associated with neurologic manifestations, including headache, dizziness, hypogeusia, and hyposmia. Reference Mao, Wang and Chen1 Beside hypogeusia and hyposmia, there has been increased reporting of distinct peripheral nervous system (PNS) diseases in COVID-19 patients.

Guillain Barre syndrome (GBS) is an inflammatory disease of the PNS, characterized by rapidly progressive, symmetrical, and typically ascending weakness of the limbs with reduced or absent deep tendon reflexes, and upper and lower extremities non-length-dependent paresthesia and sensory symptoms at onset. Cranial nerves involvement can also be present in GBS patients, with facial and bulbar muscles often being affected. Reference Leonhard, Mandarakas and Gondim2 GBS can be classified into different distinct clinical variants including classical sensorimotor, paraparetic, pure motor, pure sensory, Miller Fisher syndrome (MFS), pharyngeal-cervical-brachial variant (PCB), bilateral facial palsy with paranesthesia, and Bickerstaff brainstem encephalitis. Reference Hiew, Ramlan, Viswanathan and Puvanarajah3 Another classification of GBS based on the electromyography (EMG) findings has also been described, with acute inflammatory demyelinating polyneuropathy (AIDP) being the most common variant. Other EMG variants of GBS according to this classification include acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN). Reference Dimachkie and Barohn4

GBS has been linked to a variety of causative pathogens; campylobacter jejuni (C. jejuni), cytomegalovirus (CMV), hepatitis E virus, mycoplasma pneumoniae, Epstein–Barr virus (EBV), and Zika virus. Reference Nachamkin, Allos and Ho5–Reference Orlikowski, Porcher and Sivadon-Tardy8 The emergence of Zika virus epidemic in 2016 was noticeably linked to increased incidence of GBS. Reference Counotte, Meili, Taghavi, Calvet, Sejvar and Low9 GBS has also been linked to Middle East respiratory syndrome coronavirus (MERS-CoV) which is genetically similar to SARS-CoV-2 and was responsible for the outbreak of Middle East Respiratory Syndrome in 2013. Reference Kim, Heo and Kim10 In January 2020, the first case of GBS due to SARS-CoV-2 infection was documented in China. Reference Zhao, Shen, Zhou, Liu and Chen11 In this article, we are reviewing all the published cases of GBS that have been linked to SARS-CoV-2, to study their clinical presentations, the average latency period till the onset of GBS symptoms, the global distribution of these cases, and the findings of the ancillary GBS investigations.

Methods

We searched PubMed, EMBASE, and Google scholar and included all papers with full text available in English or Spanish and reporting original data of patients with GBS and recent COVID infection. This systematic literature review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Figure 1). Reference Moher, Liberati, Tetzlaff and Altman12 We used the following keywords on our search: GBS, MFS, COVID-19, SARS-CoV2, and neurological manifestations, and these databases were searched from August 26, 2020 and to February 7, 2021. Titles and abstracts were screened by two researchers (M. Aladawi and M. Elfil). The full texts of the selected papers were read in full by five researchers (M. Aladawi, B. Abu-Esheh, D. Abu Jazar, A. Armouti, and A. Bayoumi), and their extracted data were then revised by M. Aladawi.

Figure 1: PRISMA figure showing the steps of literature search and paper selection for the systematic review.

We included all papers, reports, or bulletins with the full text available in English or Spanish, reporting data of patients with GBS and a probable or confirmed recent COVID-19 diagnosis. Preidentified exclusion criteria were: (1) GBS with proven triggering infection other than SARS-CoV2 (e.g., C. jejuni), (2) presence of alternative diagnosis for weakness (e.g., critical illness neuropathy), and (3) latency period between COVID-19 infection and the onset of GBS symptoms of more than 6 weeks. Variables of interest were demographics, COVID-19 diagnostic investigations, latency between constitutional viral symptoms and neurological symptoms, presence of a negative SARS-Cov2 polymerase chain reaction (PCR) at the time of neurological manifestations (Table 1). Studied variables of cases with confirmed COVID-19 infection were pooled into another table to identify clinical characteristics (viral symptoms and neurological symptoms), GBS ancillary diagnostic investigations (cerebrospinal fluid [CSF] findings and testing for antiganglioside antibodies), the predominant clinical and electrophysiological variants of COVID-19-related GBS, received immunomodulatory therapy, disease progression, and clinical outcome (Table 2).

Table 1: Demographics, diagnostic confirmation of COVID-19, latency duration of neurologic symptoms, and PCR testing at the time of neurological manifestations of both suspected and confirmed cases of COVID-19

Table 2: Demographics, clinical features, and GBS classification in patients with confirmed cases of COVID-19

AIDP= acute inflammatory demyelinating polyneuropathy; AMAN=acute motor axonal neuropathy; AMSAN=acute motor and sensory axonal neuropathy; CSF=cerebrospinal fluid; GBS=Guillain Barre syndrome; ICU=intensive care unit; IVIG=intravenous immunoglobulin; PLEX=plasmapheresis.

Cases were classified according to the reported diagnostic certainty levels for GBS and COVID-19 infection. To classify the diagnosis of GBS, we employed the Brighton Collaboration Criteria. Reference Fokke, van den Berg, Drenthen, Walgaard, van Doorn and Jacobs13 The diagnostic certainty of COVID-19 infection was classified as confirmed and suspected. As confirmed cases were identified by the presence of positive PCR at the time of arboviral symptoms or the presence of positive SARS-CoV2 antibodies whether during arboviral or neurological presentation as in some cases GBS was the presenting manifestation.

Results

We identified 1450 articles in the databases researched, of which 79 papers were included in our systematic review (66 case reports and 13 cases series). The selected studies reported on a total of 109 GBS cases with a confirmed or a suspected COVID-19 infection. One case was excluded as it met one of the exclusion criteria; the latency between the onset of COVID-19 infection and the GBS onset of symptoms was 53 d (>6 weeks). Reference Raahimi, Kane, Moore and Alareed93

The applied investigations in confirming COVID-19 infection at the time of arboviral symptoms were COVID-19 PCR testing, detection of SARS-CoV2 antibodies, and suggestive features on chest radiography. Cases with either positive PCR or SARS-CoV2 antibodies were categorized as confirmed cases, whereas patients diagnosed based on abnormal chest radiographs or clinical suspicion only were categorized as suspected cases. We have identified 99 cases of COVID-19 complicated by GBS that has been confirmed with either PCR testing or serology (Table 1). Table 1 also includes the latency period between arboviral symptoms and neurologic manifestations, the country of reported cases, and repeat COVID-19 PCR at the time of neurological symptoms either from nasopharyngeal, swabs, or in the CSF.

The global distribution of cases was as follows: 32 cases in Italy, 16 cases in the United States, 12 cases in Spain, 9 cases in Iran, 6 cases in France, 6 cases in the United Kingdom, 5 cases in India, 4 cases in Germany, 4 cases in Switzerland, 2 cases in China, 1 case in Guinea, 1 case in Austria, 1 case in Brazil, 1 case in Canada, 1 case in Columbia, 1 case in Japan, 1 case in Morocco, 1 case in Netherlands, 1 case in Sudan, 1 case in Tanzania, 1 case in Turkey, and 1 case in Saudi Arabia.

At the time of the patient’s demonstrated neurologic signs and symptoms, repeat SARS-CoV2 PCR swab was negative in 23 cases. Reverse transcription PCR (RT-PCR) for SARS-CoV-2 in the CSF was performed in 50 cases in which it was negative. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d (Table 2). There were two cases where neurological manifestations have preceded arboviral symptoms, and nine cases where patients only presented with neurologic deficits with no symptoms of COVID-19, but they had positive COVID-19 testing.

Table 2 shows the pooled data of GBS cases that have been preceded by a confirmed COVID-19 infection. There was a total of 99 cases (71 males and 28 females), the average age was 56.07 years. The most common arboviral symptoms prior to GBS were fever, dry cough, dyspnea, and gastrointestinal symptoms. There were four cases which did not report patient’s arboviral symptoms prior to GBS manifestations. The most commonly reported neurological signs and symptoms were ascending motor weakness (tetraparesis and paraparesis), diminished deep tendon reflexes, sensory disturbances (paresthesia), sensory loss, and facial palsy. GBS was complicated by respiratory failure in 30 cases and dysautonomia in 20 cases.

Clinical GBS variants have been identified in these cases. The most commonly reported GBS variants were classical sensorimotor GBS (64 cases), followed by paraparetic GBS (16 cases), MFS (9 cases), facial diplegia with paresthesia (3 cases), pharyngeal-cervical-brachial GBS (2 cases), and pure sensory GBS (1 case). There were four cases that could not be classified into any of the GBS clinical variants. CSF analysis was performed in 86 cases. Seventy-four cases have shown albuminocytologic dissociation (normal CSF protein <45 mg/dl Reference Bourque, Breiner and Moher94 ), 2 cases have shown oligoclonal band, and 10 cases had no abnormalities in the CSF analysis. Antiganglioside antibodies were investigated in 50 cases. The majority of cases had negative antiganglioside antibodies (43 cases). Each of anti-GM1, anti-GD1a, and anti-GD1b were positive in three cases; anti-GM2 was positive in two cases; and each of anti-GD3, anti-GQ1b, anti-GT1b, and anti-Gal-C were positive in one case.

Electromyography (EMG) was performed in 77 cases. The predominant EMG variant of GBS was AIDP (59 cases), followed by AMSAN (10 cases), and AMAN (8 cases). Eighty-nine reports confirmed the use of immunomodulatory treatment for GBS. Seventy-two cases received intravenous immunoglobulin (IVIG) therapy, 10 cases were treated with plasmapheresis (PLEX), and 7 cases were treated with both IVIG and PLEX. In terms of disease progression and the clinical outcomes, 40 cases required admission to the intensive care unit (ICU), 33 cases required mechanical ventilation, and 6 cases were complicated by death.

Brighton criteria were applied to improve the diagnostic certainty for the cases; valid symptomatology included bilateral and flaccid weakness of limbs at the time of presentation, decreased deep tendon reflexes in affected limbs, the presence of a monophasic course of neurologic symptoms, CSF cell count <50/μl, elevated CSF protein, EMG findings consistent with one of the subtypes of GBS, and the absence of alternative diagnosis. Accordingly, cases were classified from level 1–4 of diagnostic certainty. Reference Fokke, van den Berg, Drenthen, Walgaard, van Doorn and Jacobs13 Cases with MFS where the complete triad of ophthalmoplegia, ataxia, and areflexia was not present were classified as level 4. Reference Tan, Razali, Goh and Shahrizaila95 Cases with other variants such as facial diplegia with paresthesia, PCB variant, and pure sensory GBS has been excluded. Accordingly, 51 cases have fulfilled level 1 of diagnostic certainty, 26 cases have fulfilled level 2, 7 cases have fulfilled level 3, and 9 cases fulfilled level 4. We have concluded that the reported cases have a high-diagnostic certainty of GBS as most of the cases have been classified into level 1–3 of Brighton criteria.

Discussion

Our systematic review shows that the published literature on COVID-19-related GBS commonly report a classic sensorimotor variant of GBS with often facial palsy and a demyelinating electrophysiological subtype. The disease course is frequently severe with high rates of respiratory dysfunction and ICU admission. Reference Shang, Zhu, Baker, Feng, Zhou and Zhang96 The time elapsed between infection and neurologic manifestations, and a negative PCR in spinal fluid might suggest that there is a postinfectious mechanism implicated in the etiology of COVID-19-related GBS. However, these results should be interpreted with caution as the cases included in this systematic review varied widely in diagnostic ascertainment and reporting of different variables. Moreover, the reported cases were limited to certain geographical areas, which might provide a source of bias.

The constellation of sensorimotor signs with facial palsy, respiratory insufficiency, and a demyelinating electrophysiological subtype has been described in GBS patients with other viral infections such as CMV and Zika virus, which might indicate that this clinical and electrophysiological variant of GBS is related to viral infections in general. Reference Orlikowski, Porcher and Sivadon-Tardy8,Reference Leonhard, Bresani-Salvi and Lyra Batista97 On the other hand, C. jejuni is typically associated with pure motor and axonal type of GBS. Reference Rees and Hughes98 Although GBS is generally more common in men as compared with women, Reference Katirji, Ruff and Kaminski99 in our systematic review, we have found that the male to female ratio was 2.5:1 which is significantly higher than what is usually reported. Reference Piccione, Salame, Katirji, Katirji, Kaminski and Ruff100 This suggests that men might be more prone to COVID-19-related GBS.

In our review, the most common arboviral symptoms were fever and dry cough, which is typical in COVID-19 infection. Reference Eastin and Eastin101 We could not identify a specific arboviral symptom that could be typically preceding the development of GBS. However, we have identified two cases in which GBS manifestations preceded COVID-19 arboviral symptoms, and nine cases that did not present with arboviral symptoms initially. This chronology of GBS preceding the arboviral symptoms has not been previously reported with GBS related to other viral agents. In addition, the asymptomatic infection of COVID-19 might limit the ability to accurately determine the latency period between viral symptoms and the GBS presentation.

The mean duration between the onset of COVID-19 infectious symptoms and GBS presentation was 2 weeks, which is similar to other infections preceding GBS. Reference Rees, Soudain, Gregson and Hughes102 The latency between COVID-19 infection and GBS was more than a week for most cases, but it should be taken into consideration that COVID-19 can initially be asymptomatic which makes the latency duration arguably longer than reported. This suggests a postinfectious immunopathogenesis rather than direct neuronal damage or a parainfectious mechanism. The fact that COVID-19 PCR of the CSF was not positive in a single report, the negativity of repeat nasopharyngeal PCR at the time of symptoms in almost one-third of the cases, and the absence of elevated white blood cell count in the CSF in majority of cases, further argues against the assumption of COVID-19 infection being directly responsible for the GBS development in this proportion of patients.

Despite the fact that previous epidemiological studies have suggested that COVID-19 might not be associated with GBS, Reference Keddie, Pakpoor and Mousele103 the chronology of publication of the COVID-19-related GBS cases followed the same pattern of the global spread of COVID-19, as the first cases report was from China followed by Italy, Iran, and USA indicates a positive association. Reference Zhao, Shen, Zhou, Liu and Chen11,Reference Sedaghat and Karimi24,Reference Toscano, Palmerini and Ravaglia48,Reference Virani, Rabold and Hanson65 GBS has been historically related to various pathogens including C. jejuni, M. pneumoniae, EBV, CMV, Hepatitis E virus, and Zika virus. Reference Nachamkin, Allos and Ho5–Reference Counotte, Meili, Taghavi, Calvet, Sejvar and Low9 However, in certain pathogens such as Hepatitis E virus, this association has not been established globally, as it was only reported in Netherlands and Bangladesh. Reference Liu and Ma104 Therefore, immunogenicity of COVID-19 in the development of GBS should consider the variations between different populations, Reference Hardy, Blum, McCombe and Reddel105–Reference Nyati, Prasad and Verma108 as epidemiologic studies involving certain populations might introduce bias in reporting results.

Interestingly, almost half of the cases were tested for the presence of antiganglioside antibodies in serum. There were only seven cases have tested positive for different antiganglioside antibodies. Historically, different antigangliosides have been linked to different variants of GBS, such as anti-GQ1b in MFS and anti-GD1a in PCB variant. Reference Willison and O’Hanlon109,Reference Nagashima, Koga, Odaka, Hirata and Yuki110 Antiganglioside antibodies are considered to be biomarkers of axonal injury rather demyelination, as they directly target the neuronal membrane gangliosides. Reference Willison and Yuki111 Because most of the COVID-19-related GBS cases reported a demyelinating variant of GBS, it can be anticipated that the presence of antiganglioside antibodies would be low. Thus, the spectrum of immune cascade in COVID-19-related GBS should be expanded by studying other different antibodies affecting the myelin sheath, Schwann cell components, and the neuronal axolemma. Reference Soliven112,Reference Stathopoulos, Alexopoulos and Dalakas113 One case was reported with positive NF-155 and NF-186 antibodies, which are structural proteins in the node of Ranvier. Reference Tard, Maurage and de Paula22

The possible role of host immunogenetic background in the development of GBS and its variants has been related to human leukocyte antigen (HLA) polymorphism in different populations, this observation might explain the increased reporting of COVID-19 related GBS in the Italy, as one-third of the cases identified in our review were Italian. Reference Rodríguez, Rojas and Pacheco114,Reference Safa, Azimi, Sayad, Taheri and Ghafouri-Fard115 The role of HLA polymorphism in COVID-19 related GBS has been emphasized in one of the cases reported by Gigli et al., Reference Gigli, Vogrig and Nilo36 in which SARS-CoV2 antibodies were detected in the CSF. Interestingly, HLA analysis of the reported case showed several HLA alleles that are known to be associated with GBS, such as: HLA-A33, Reference Guo, Wang, Li, Liu and Wang116 DRB1 * 03:01, Reference Hasan, Zalzala and Mohammedsalih117 and DQB1 * 05:01. Reference Schirmer, Worthington and Solloch118

With the emergence of COVID-19 pandemic, there have been increasing reports of various neurological complications in infected patients, which was well documented and studied in other coronaviruses. Reference Mao, Wang and Chen1 Genomic analysis shows that SARS-CoV-2 is in the same beta-coronavirus (βCoV) clade as MERS-CoV and SARS-CoV, and shares a highly homological sequence with SARS-CoV. Reference Hu, Liu, Zhao, Zhuang, Xu and He119 There has been clinical evidence of neuromuscular sequela in SARS CoV and MERS infection and the most documented neuromuscular syndromes related to these viruses are critical illness polyneuropathy and myopathy, which are hypothesized to occur in the context of severe inflammatory response syndrome (SIRS). Reference Tsai, Hsieh and Chang120 Cases of MERS-related GBS have been reported, yet GBS in these cases has been linked to the treatment received for MERS infection, such as interferon alpha2 and Lopinavir/ritonavir. Reference Kim, Heo and Kim10 In contrast to MERS, SARS-CoV2 is likely associated with GBS.

Conclusion

Based on this systematic review, most cases of COVID-19-related GBS are of the sensorimotor demyelinating subtype with frequent facial palsy. The latency between infection and onset of neurologic symptoms as well as the absence of viral genome detected by PCR suggest a postinfectious, rather than a direct infectious or para-infectious mechanism. Global reporting of COVID-19-related GBS cases, in addition to testing for different antibodies to different structural proteins and glycolipids in the peripheral nerves, would improve the understanding of the immunological cascade of COVID-19-related GBS. Finally, early diagnosis and identification of GBS in COVID-19 patients is important as COVID-19-related GBS might be associated with a severe disease course that frequently requires ICU admission and mechanical ventilation.

Disclosures

The authors declare no conflicts of interest.

Statement of Authorship

MA: contributed with the conception and design of the study, acquisition, analysis, and interpretation of data, drafting, revising, and final approval of the article.

ME: contributed with the conception and design of the study, acquisition, analysis and interpretation of data, drafting, revising, and final approval of the article.

BA: contributed with acquisition and extraction of data and drafting the article.

DA: contributed with extraction of data and final approval of the article.

AA: contributed with extraction of data and final approval of the article.

AB: contributed with extraction of data and final approval of the article.

EP: contributed with conception and design of the study, drafting, revising and final approval of the article.

References

Mao, L, Wang, M, Chen, S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. SSRN Electron J. 2020. doi: 10.2139/ssrn.3544840 Google Scholar
Leonhard, SE, Mandarakas, MR, Gondim, FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671–83. doi: 10.1038/s41582-019-0250-9 CrossRefGoogle ScholarPubMed
Hiew, FL, Ramlan, R, Viswanathan, S, Puvanarajah, S. Guillain-Barré syndrome, variants & forms fruste: reclassification with new criteria. Clin Neurol Neurosurg. 2017;158:114–18. doi: 10.1016/j.clineuro.2017.05.006 CrossRefGoogle ScholarPubMed
Dimachkie, MM, Barohn, RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31:491–510. doi: 10.1016/j.ncl.2013.01.005 CrossRefGoogle ScholarPubMed
Nachamkin, I, Allos, BM, Ho, T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev. 1998;11:555–67.CrossRefGoogle ScholarPubMed
Meyer Sauteur, PM, Huizinga, R, Tio-Gillen, AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: a case-control study. Ann Neurol. 2016;80:566–80.CrossRefGoogle ScholarPubMed
Masajtis-Zagajewska, A, Muras, K, Mochecka-Thoelke, A, Kurnatowska, I, Nowicki, M. Guillain-Barre syndrome in the course of EBV infection after kidney transplantation—a case report. Ann Transplant. 2012;17:133–37.Google ScholarPubMed
Orlikowski, D, Porcher, R, Sivadon-Tardy, V, et al. Guillain-barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52:837–44. doi: 10.1093/cid/cir074 CrossRefGoogle ScholarPubMed
Counotte, MJ, Meili, KW, Taghavi, K, Calvet, G, Sejvar, J, Low, N. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: a living systematic review [version 1; peer review: 2 approved]. F1000Research. 2019;8. doi: 10.12688/f1000research.19918.1 CrossRefGoogle Scholar
Kim, JE, Heo, JH, Kim, HO, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. 2017;13:227–33. doi: 10.3988/jcn.2017.13.3.227 CrossRefGoogle ScholarPubMed
Zhao, H, Shen, D, Zhou, H, Liu, J, Chen, S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19:383–84. doi: 10.1016/S1474-4422(20)30109-5 CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097 CrossRefGoogle ScholarPubMed
Fokke, C, van den Berg, B, Drenthen, J, Walgaard, C, van Doorn, PA, Jacobs, BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43. doi: 10.1093/brain/awt285 CrossRefGoogle ScholarPubMed
Diez-Porras, L, Vergés, E, Gil, F, Vidal, MJ, Massons, J, Arboix, A. Guillain-Barré-Strohl syndrome and COVID-19: case report and literature review. Neuromuscul Disord. 2020;30:859–861. doi: 10.1016/j.nmd.2020.08.354 CrossRefGoogle ScholarPubMed
Granger, A, Omari, M, Jakubowska-Sadowska, K, Boffa, M, Zakin, E. SARS-CoV-2–Associated Guillain–Barre syndrome with good response to plasmapheresis. J Clin Neuromuscular Dis. 2020;22:58–9.CrossRefGoogle ScholarPubMed
Hirayama, T, Hongo, Y, Kaida, K, Kano, O. Guillain-Barré syndrome after COVID-19 in Japan. BMJ Case Rep. 2020;13:1–4. doi: 10.1136/bcr-2020-239218 CrossRefGoogle ScholarPubMed
Liberatore, G, De Santis, T, Doneddu, PE, Gentile, F, Albanese, A, Nobile-Orazio, E. Clinical reasoning: a case of COVID-19-associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Neurology. 2020;95:978–83. doi: 10.1212/WNL.0000000000010817 CrossRefGoogle ScholarPubMed
Nanda, S, Handa, R, Prasad, A, et al. Covid-19 associated Guillain-Barre syndrome: contrasting tale of four patients from a tertiary care centre in India. Am J Emerg Med. 2021;39:125–28. doi: 10.1016/j.ajem.2020.09.029 CrossRefGoogle ScholarPubMed
Atakla, HG, Noudohounsi, MMUD, Sacca, H, Tassiou, NRA, Noudohounsi, WC, Houinato, DS. Acute Guillain-Barré polyradiculoneuritis indicative of covid-19 infection: a case report. Pan Afr Med J. 2020;35:1–6. doi: 10.11604/pamj.supp.2020.35.150.25745 CrossRefGoogle ScholarPubMed
Rajdev, K, Victor, N, Buckholtz, ES, et al. A case of Guillain-Barré syndrome associated with COVID-19. J Investig Med High Impact Case Rep. 2020;8. doi: 10.1177/2324709620961198 Google ScholarPubMed
Senel, M, Abu-Rumeileh, S, Michel, D, et al. Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement. Eur J Neurol. 2020;27:2378–80. doi: 10.1111/ene.14473 CrossRefGoogle ScholarPubMed
Tard, C, Maurage, CA, de Paula, AM, et al. Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barré syndrome: Evidence for a nodo-paranodopathy. Neurophysiol Clin. 2020;50:397–99. doi: 10.1016/j.neucli.2020.09.007 CrossRefGoogle ScholarPubMed
Chan, M, Han, SC, Kelly, S, Tamimi, M, Giglio, B, Lewis, A. A case series of Guillain-Barré Syndrome following Covid-19 infection in New York. Neurol Clin Pract. Published online 2020. doi: 10.1212/cpj.0000000000000880 Google Scholar
Sedaghat, Z, Karimi, N. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. 2020;(January).Google Scholar
Ebrahimzadeh, SA, Ghoreishi, A, Rahimian, N. Guillain-Barré Syndrome associated with the coronavirus disease 2019 (COVID-19). Neurol Clin Pract. 2020;2019. doi: 10.1212/cpj.0000000000000879 CrossRefGoogle Scholar
Arnaud, S, Budowski, C, Ng Wing Tin, S, Degos, B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin Neurophysiol. 2020;131:1652–54. doi: 10.1016/j.clinph.2020.05.003 CrossRefGoogle ScholarPubMed
Paybast, S, Gorji, R, Mavandadi, S. Guillain-Barré syndrome as a neurological complication of novel COVID-19 infection: a case report and review of the literature. Neurologist. 2020;25:101–103. doi: 10.1097/NRL.0000000000000291 CrossRefGoogle ScholarPubMed
Coen, M, Jeanson, G, Culebras Almeida, LA, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020;87:111–12. doi: 10.1016/j.bbi.2020.04.074 CrossRefGoogle ScholarPubMed
Dinkin, M, Gao, V, Kahan, J, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020;95:221–23. doi: 10.1212/WNL.0000000000009700 CrossRefGoogle ScholarPubMed
Manganotti, P, Bellavita, G, D’Acunto, L, et al. Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series. J Med Virol. 2020:1–9. doi: 10.1002/jmv.26289 Google ScholarPubMed
Fernández-Domínguez, J, Ameijide-Sanluis, E, García-Cabo, C, García-Rodríguez, R, Mateos, V. Miller–Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19). J Neurol. 2020;267:2495–96. doi: 10.1007/s00415-020-09912-2 CrossRefGoogle Scholar
Hutchins, KL, Jansen, JH, Comer, AD, et al. COVID-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome. Am J Neuroradiol. 2020;41:1707–11. doi: 10.3174/ajnr.A6654 Google ScholarPubMed
Kilinc, D, van de Pasch, S, Doets, AY, Jacobs, BC, van Vliet, J, Garssen, MPJ. Guillain–Barré syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020;27:1757–58. doi: 10.1111/ene.14398 CrossRefGoogle ScholarPubMed
Naddaf, E, Laughlin, RS, Klein, CJ, et al. Guillain-Barré syndrome in a patient with evidence of recent SARS-CoV-2 infection. Mayo Clin Proc. 2020;95:1799–801. doi: 10.1016/j.mayocp.2020.05.029 CrossRefGoogle Scholar
Abrams, RMC, Kim, BD, Markantone, DM, et al. Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease. J Neurovirol. 2020;26:797–99. doi: 10.1007/s13365-020-00884-7 CrossRefGoogle ScholarPubMed
Gigli, GL, Vogrig, A, Nilo, A, et al. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci. 2020;41:3391–94. doi: 10.1007/s10072-020-04787-7 CrossRefGoogle ScholarPubMed
Bracaglia, M, Naldi, I, Govoni, A, Brillanti Ventura, D, De Massis, P. Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2. J Neurol. 2020;267:3166–168. doi: 10.1007/s00415-020-10014-2 CrossRefGoogle ScholarPubMed
Sidig, A, Abbasher, K, Digna, MF, et al. COVID-19 and Guillain-Barre Syndrome – a case report. Res Sq Prepr. Published online 2020:1–8.Google Scholar
Lascano, AM, Epiney, JB, Coen, M, et al. SARS-CoV-2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome. Eur J Neurol. 2020;27:1751–53. doi: 10.1111/ene.14368 CrossRefGoogle ScholarPubMed
Camdessanche, JP, Morel, J, Pozzetto, B, Paul, S, Tholance, Y, Botelho-Nevers, E. COVID-19 may induce Guillain–Barré syndrome. Rev Neurol (Paris). 2020;176:516–18. doi: 10.1016/j.neurol.2020.04.003 CrossRefGoogle ScholarPubMed
Abolmaali, M, Heidari, M, Zeinali, M, et al. Guillain–Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series. J Clin Neurosci. 2021;83:119–22. doi: 10.1016/j.jocn.2020.11.013 CrossRefGoogle ScholarPubMed
Chan, JL, Ebadi, H, Sarna, JR. Guillain-Barré syndrome with facial Diplegia related to SARS-CoV-2 infection. Can J Neurol Sci/J Can des Sci Neurol. Published online 2020:1–3. doi: 10.1017/cjn.2020.106 CrossRefGoogle Scholar
Sancho-Saldaña, A, Lambea-Gil, Á, Capablo Liesa, JL, et al. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. Clin Med J R Coll Physicians London. 2020;20:E93–94. doi: 10.7861/CLINMED.2020-0213 Google ScholarPubMed
Assini, A, Benedetti, L, Di Maio, S, Schirinzi, E, Del Sette, M. Correction to: New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases (Neurological Sciences, (2020), 41, 7, (1657–1658), 10.1007/s10072-020-04484-5). Neurol Sci. 2020;41:2307. doi: 10.1007/s10072-020-04517-z CrossRefGoogle Scholar
Frank, CHM, Almeida, TVR, Marques, EA, et al. Guillain–Barré syndrome associated with SARS-CoV-2 infection in a pediatric patient. J Trop Pediatr. Published online 2020:1–6. doi: 10.1093/tropej/fmaa044 CrossRefGoogle Scholar
Juliao Caamaño, DS, Alonso Beato, R. Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020;77:230–32. doi: 10.1016/j.jocn.2020.05.016 CrossRefGoogle ScholarPubMed
Oguz-Akarsu, E, Ozpar, R, Mirzayev, H, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle and Nerve. 2020;2:54–57. doi: 10.1002/mus.26992 Google Scholar
Toscano, G, Palmerini, F, Ravaglia, S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–76. doi: 10.1056/NEJMc2009191 CrossRefGoogle ScholarPubMed
Reyes-Bueno, JA, García-Trujillo, L, Urbaneja, P, et al. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020;27:1759–61. doi:10.1111/ene.14383 CrossRefGoogle ScholarPubMed
Bigaut, K, Mallaret, M, Baloglu, S, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflammation. 2020;7:4–6. doi: 10.1212/NXI.0000000000000785 CrossRefGoogle ScholarPubMed
Padroni, M, Mastrangelo, V, Asioli, GM, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? J Neurol. 2020;267:1877–79. doi: 10.1007/s00415-020-09849-6 CrossRefGoogle Scholar
Tiet, MY, Alshaikh, N. Guillain-Barré syndrome associated with COVID-19 infection: a case from the UK. BMJ Case Rep. 2020;13:1–4. doi: 10.1136/bcr-2020-236536 CrossRefGoogle ScholarPubMed
Ameer, N, Shekhda, KM, Cheesman, A. Guillain-Barré syndrome presenting with COVID-19 infection. BMJ Case Rep. 2020;13:3–5. doi: 10.1136/bcr-2020-236978 CrossRefGoogle ScholarPubMed
Wada, S, Nagasaki, Y, Arimizu, Y, et al. Neurological disorders Identified during treatment of a SARS-CoV-2 infection. Intern Med. 2020;59:2187–89. doi: 10.2169/internalmedicine.5447-20 CrossRefGoogle ScholarPubMed
Ray, A. Miller Fisher syndrome and COVID-19: Is there a link. BMJ Case Rep. 2020;13:19–22. doi: 10.1136/bcr-2020-236419 CrossRefGoogle ScholarPubMed
Guijarro-Castro, C, Rosón-González, M, Abreu, A, García-Arratibel, A, Ochoa-Mulas, M. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases. Neurologia. 2020;35:412–15. doi: 10.1016/j.nrl.2020.06.002 CrossRefGoogle ScholarPubMed
Gutiérrez-Ortiz, C, Méndez-Guerrero, A, Rodrigo-Rey, S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95:e601–605. doi: 10.1212/WNL.0000000000009619 CrossRefGoogle ScholarPubMed
Agosti, E, Giorgianni, A, D’Amore, F, Vinacci, G, Balbi, S, Locatelli, D. Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci. Published online 2020. doi: 10.1007/s10072-020-04553-9 CrossRefGoogle Scholar
Khalifa, M, Zakaria, F, Ragab, Y, et al. Guillain-Barré syndrome associated with severe acute respiratory syndrome coronavirus 2 detection and coronavirus disease 2019 in a child. J Pediatric Infect Dis Soc. 2020;9:510–13. doi: 10.1093/jpids/piaa086 CrossRefGoogle ScholarPubMed
Farzi, MA, Ayromlou, H, Jahanbakhsh, N, Bavil, PH, Janzadeh, A, Shayan, FK. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J Neuroimmunol. 2020;346:577294. doi: 10.1016/j.jneuroim.2020.577294 CrossRefGoogle Scholar
Alberti, P, Beretta, S, Piatti, M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol NeuroInflammation. 2020;7:1–3. doi: 10.1212/NXI.0000000000000741 CrossRefGoogle ScholarPubMed
Rana, S, Lima, AA, Chandra, R, et al. Novel coronavirus (Covid-19)-associated Guillain-Barré syndrome: Case report. J Clin Neuromuscul Dis. 2020;21:240–42. doi: 10.1097/cnd.0000000000000309 CrossRefGoogle ScholarPubMed
Korem, S, Gandhi, H, Dayag, DB. Guillain-Barré syndrome associated with COVID-19 disease. BMJ Case Rep. 2020;13. doi: 10.1136/bcr-2020-237215 CrossRefGoogle ScholarPubMed
Civardi, C, Collini, A, Geda, DJ, Geda, C. Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry. 2020;91:1361–62. doi: 10.1136/jnnp-2020-324279 CrossRefGoogle ScholarPubMed
Virani, A, Rabold, E, Hanson, T, et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. IDCases. 2020;20:e00771. doi: 10.1016/j.idcr.2020.e00771 CrossRefGoogle ScholarPubMed
Khaja, M, Roa Gomez, GP, Santana, Y, et al. A 44-year-old hispanic man with loss of taste and bilateral facial weakness diagnosed with Guillain-Barré syndrome and Bell’s Palsy associated with SARS-CoV-2 infection treated with intravenous immunoglobulin. Am J Case Rep. 2020;21:1–6. doi: 10.12659/AJCR.927956 CrossRefGoogle ScholarPubMed
Lampe, A, Winschel, A, Lang, C, Steiner, T. Guillain-Barré syndrome and SARS-CoV-2. Neurol Res Pract 2020;2:19.CrossRefGoogle ScholarPubMed
Ottaviani, D, Boso, F, Tranquillini, E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci. 2020;41:1351–54. doi: 10.1007/s10072-020-04449-8 CrossRefGoogle ScholarPubMed
Scheidl, E, Canseco, DD, Hadji-Naumov, A, Bereznai, B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst. 2020;25(2):204–207. doi: 10.1111/jns.12382 CrossRefGoogle ScholarPubMed
El Otmani, H, El Moutawakil, B, Rafai, MA, et al. Covid-19 and Guillain-Barré syndrome: more than a coincidence! Rev Neurol (Paris). 2020;176:518–19. doi: 10.1016/j.neurol.2020.04.007 CrossRefGoogle Scholar
Lantos, JE, Strauss, SB, Lin, E. COVID-19–associated Miller Fisher syndrome: MRI findings. Am J Neuroradiol. 2020;41:1184–86. doi: 10.3174/ajnr.A6609 CrossRefGoogle ScholarPubMed
Riva, N, Russo, T, Falzone, YM, et al. Post-infectious Guillain–Barré syndrome related to SARS-CoV-2 infection: a case report. J Neurol. 2020;267:2492–94. doi: 10.1007/s00415-020-09907-z CrossRefGoogle ScholarPubMed
Helbok, R, Beer, R, Löscher, W, et al. Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2. Eur J Neurol. 2020;27:1754–56. doi: 10.1111/ene.14388 CrossRefGoogle Scholar
Webb, S, Wallace, VCJ, Martin-Lopez, D, Yogarajah, M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Rep. 2020;13:1–4. doi: 10.1136/bcr-2020-236182 CrossRefGoogle ScholarPubMed
Pfefferkorn, T, Dabitz, R, von Wernitz-Keibel, T, Aufenanger, J, Nowak-Machen, M, Janssen, H. Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19. J Neurol. 2020;267:1883–84. doi: 10.1007/s00415-020-09897-y CrossRefGoogle Scholar
Dufour, C, Co, T-K, Liu, A. GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome – a case report, systemic review and implication for vaccine development. Brain, Behav Immun – Health. 2021;12:100203. doi: 10.1016/j.bbih.2021.100203 CrossRefGoogle ScholarPubMed
Jones, R, Kolbe, H, Barton, A. Post Covid-19 Guillain-Barre syndrome: case report. Morecambe Bay Med J. 2020;8:229–31.CrossRefGoogle Scholar
Ghosh, R, Roy, D, Sengupta, S, Benito-León, J. Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19. J Neurovirol. 2020;26:964–66. doi: 10.1007/s13365-020-00908-2 CrossRefGoogle ScholarPubMed
Mackenzie, N, Lopez-Coronel, E, Alberto Dau, C, et al. A concomitant Guillain-Barre syndrome with COVID-19: a first case-report in Colombia. 1–9. https://doi.org/10.21203/rs.3.rs-61279/v1 CrossRefGoogle Scholar
Charra, B. Guillain Barre syndrome & Covid-19: a case report. Ann Clin Med Case Rep. Published online 2021:V5.Google Scholar
Petrelli, C, Scendoni, R, Paglioriti, M, Logullo, FO. Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview. J Clin Neuromuscul Dis. 2020;22:120–21. doi: 10.1097/cnd.0000000000000322 CrossRefGoogle ScholarPubMed
Yaqoob, H, Jain, A, Epelbaum, O. A unique case of Guillain-Barré syndrome related to COVID-19 infection. Chest. 2020;158:A771. doi: 10.1016/j.chest.2020.08.718 CrossRefGoogle Scholar
Bueso, T, Montalvan, V, Lee, J, et al. Guillain-Barre syndrome and COVID-19: a case report. Clin Neurol Neurosurg. 2021;200:2020–22. doi: 10.1016/j.clineuro.2020.106413 CrossRefGoogle ScholarPubMed
Manji, HK, George, U, Mkopi, NP, Manji, KP. Guillain-Barré syndrome associated with COVID-19 infection. Pan Afr Med J. 2020;35:118. doi: 10.11604/pamj.supp.2020.35.2.25003 Google ScholarPubMed
Su, XW, Palka, S V., Rao, RR, Chen, FS, Brackney, CR, Cambi, F. SARS-CoV-2–associated Guillain-Barré syndrome with dysautonomia. Muscle and Nerve. 2020;62:E48–49. doi: 10.1002/mus.26988 CrossRefGoogle ScholarPubMed
Velayos Galán, A, del Saz Saucedo, P, Peinado Postigo, F, Botia Paniagua, E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Neurologia. 2020;35:268–69. doi: 10.1016/j.nrl.2020.04.007 CrossRefGoogle ScholarPubMed
Barrachina-Esteve, O, Palau Domínguez, A, Hidalgo-Torrico, I, Viguera Martínez, ML. Síndrome de Guillain-Barré como forma de presentación de la infección por SARS-CoV-2. Neurología. 2020;35:710–12. doi: 10.1016/j.nrl.2020.07.001 CrossRefGoogle Scholar
Marta-Enguita, J, Rubio-Baines, I, Gastón-Zubimendi, I. Síndrome de Guillain-Barré fatal tras infección por el virus SARS-CoV-2. Neurología. 2020;35:265–67. doi: 10.1016/j.nrl.2020.04.004 CrossRefGoogle Scholar
Gigli, GL, Bax, F, Marini, A, et al. Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? J Neurol. 2020;0123456789:1–3. doi: 10.1007/s00415-020-09911-3 CrossRefGoogle Scholar
Manganotti, P, Pesavento, V, Buoite Stella, A, et al. Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2. J Neurovirol. 2020;26:605–606. doi: 10.1007/s13365-020-00858-9 CrossRefGoogle Scholar
Gale, A, Sabaretnam, S, Lewinsohn, A. Guillain-Barré syndrome and COVID-19: association or coincidence. BMJ Case Rep. 2020;13:10–14. doi: 10.1136/bcr-2020-239241 CrossRefGoogle ScholarPubMed
García-Manzanedo, S, López de la Oliva Calvo, L, Ruiz Álvarez, L. Síndrome de Guillain-Barré tras infección por COVID-19. Med Clin (Barc). 2020;155:366. doi:10.1016/j.medcli.2020.06.023 CrossRefGoogle Scholar
Raahimi, MM, Kane, A, Moore, CE, Alareed, AW. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of “long COVID-19 syndrome”? BMJ Case Rep. 2021;14:1–4. doi: 10.1136/bcr-2020-240178 CrossRefGoogle Scholar
Bourque, PR, Breiner, A, Moher, D, et al. Adult CSF total protein: higher upper reference limits should be considered worldwide. a web-based survey. J Neurol Sci. 2019;396:48–51. doi:10.1016/j.jns.2018.10.033 CrossRefGoogle ScholarPubMed
Tan, CY, Razali, SNO, Goh, KJ, Shahrizaila, N. Diagnosis of Guillain-Barré syndrome and validation of the Brighton criteria in Malaysia. J Peripher Nerv Syst. 2020;25:256–64. doi: 10.1111/jns.12398 CrossRefGoogle ScholarPubMed
Shang, P, Zhu, M, Baker, M, Feng, J, Zhou, C, Zhang, H-L. Mechanical ventilation in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2020;16:1053–64. doi: 10.1080/1744666X.2021.1840355 CrossRefGoogle ScholarPubMed
Leonhard, SE, Bresani-Salvi, CC, Lyra Batista, JD. et al. Guillain-barré syndrome related to Zika virus infection: a systematic review and meta-analysis of the clinical and electrophysiological phenotype. PLoS Negl Trop Dis. 2020;14:1–24. doi: 10.1371/journal.pntd.0008264 CrossRefGoogle ScholarPubMed
Rees, JH, Hughes, RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333:1374–9.CrossRefGoogle ScholarPubMed
Katirji, B, Ruff, RL, Kaminski, HJ. Neuromuscular disorders in clinical practice. Vol. 9781461465; 2014. doi: 10.1007/978-1-4614-6567-6 CrossRefGoogle Scholar
Piccione, EA, Salame, K, Katirji, B. Guillain-Barré syndrome and related disorders BT – neuromuscular disorders in clinical practice. In: Katirji, B, Kaminski, HJ, Ruff, RL, editors. Neuromuscular Disorders in Clinical Practice. New York: Springer; 2014, pp. 573–603. doi: 10.1007/978-1-4614-6567-6_28 CrossRefGoogle Scholar
Eastin, C, Eastin, T. Clinical characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. J Emerg Med. 2020;58:711–12. doi: 10.1016/j.jemermed.2020.04.004 CrossRefGoogle Scholar
Rees, JH, Soudain, SE, Gregson, NA, Hughes, RAC. Campylobacter jejuni infection and Guillain–Barré syndrome. N Engl J Med. 1995;333:1374–79. doi: 10.1056/NEJM199511233332102 CrossRefGoogle ScholarPubMed
Keddie, S, Pakpoor, J, Mousele, C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144:682–93. doi: 10.1093/brain/awaa433 CrossRefGoogle ScholarPubMed
Liu, H, Ma, Y. Hepatitis E virus-associated Guillain-Barre syndrome: revision of the literature. Brain Behav. 2020;10:e01496. doi: 10.1002/brb3.1496 CrossRefGoogle ScholarPubMed
Hardy, TA, Blum, S, McCombe, PA, Reddel, SW. Guillain-Barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep. 2011;11:197–204. doi: 10.1007/s11882-011-0190-y CrossRefGoogle ScholarPubMed
Jahan, I, Ahammad, RU, Khalid, MM, et al. Toll-like receptor-4 299Gly allele is associated with Guillain-Barré syndrome in Bangladesh. Ann Clin Transl Neurol. 2019;6:708–15. doi: 10.1002/acn3.744 CrossRefGoogle ScholarPubMed
Jaramillo-Valverde, L, Levano, KS, Villanueva, I, et al. Guillain–Barre syndrome outbreak in Peru: association with polymorphisms in IL-17, ICAM1, and CD1. Mol Genet Genomic Med. 2019;7:e00960. doi: 10.1002/mgg3.960 CrossRefGoogle ScholarPubMed
Nyati, KK, Prasad, KN, Verma, A, et al. Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barré syndrome in Northern Indian population. J Neuroimmunol. 2010;218:116–19. doi: 10.1016/j.jneuroim.2009.10.018 CrossRefGoogle ScholarPubMed
Willison, HJ, O’Hanlon, GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol. 1999;100:3–12. doi: 10.1016/S0165-5728(99)00213-1 CrossRefGoogle ScholarPubMed
Nagashima, T, Koga, M, Odaka, M, Hirata, K, Yuki, N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64:1519–23. doi: 10.1001/archneur.64.10.1519 CrossRefGoogle ScholarPubMed
Willison, HJ, Yuki, N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591–625. doi: 10.1093/brain/awf272 CrossRefGoogle ScholarPubMed
Soliven, B. Animal models of autoimmune neuropathy. ILAR J. 2014;54:282–90. doi: 10.1093/ilar/ilt054 CrossRefGoogle ScholarPubMed
Stathopoulos, P, Alexopoulos, H, Dalakas, MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 2015;11:143–56. doi: 10.1038/nrneurol.2014.260 CrossRefGoogle Scholar
Rodríguez, Y, Rojas, M, Pacheco, Y, et al. Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15:547–62. doi: 10.1038/cmi.2017.142 CrossRefGoogle ScholarPubMed
Safa, A, Azimi, T, Sayad, A, Taheri, M, Ghafouri-Fard, S. A review of the role of genetic factors in Guillain–Barré syndrome. J Mol Neurosci. Published online 2020:1–19.CrossRefGoogle Scholar
Guo, L, Wang, W, Li, C, Liu, R, Wang, G. The association between HLA typing and different subtypes of Guillain Barré syndrome [in Chinese]. Zhonghua Nei Ke Za Zhi. 2002;41:381–3. Available at http://europepmc.org/abstract/MED/12137599 Google Scholar
Hasan, ZN, Zalzala, HH, Mohammedsalih, HR, et al. Association between human leukocyte antigen-DR and demylinating Guillain-Barre syndrome. Neurosciences (Riyadh). 2014;19:301–305.Google ScholarPubMed
Schirmer, L, Worthington, V, Solloch, U, et al. Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain–Barré syndrome. J Neurol. 2016;263:2105–13. doi: 10.1007/s00415-016-8237-6 CrossRefGoogle Scholar
Hu, T, Liu, Y, Zhao, M, Zhuang, Q, Xu, L, He, Q. A comparison of COVID-19, SARS and MERS. PeerJ. 2020;8:e9725–25. doi: 10.7717/peerj.9725 CrossRefGoogle ScholarPubMed
Tsai, L-K, Hsieh, S-T, Chang, Y-C. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan. 2005;14:113–19.Google ScholarPubMed
Figure 0

Figure 1: PRISMA figure showing the steps of literature search and paper selection for the systematic review.

Figure 1

Table 1: Demographics, diagnostic confirmation of COVID-19, latency duration of neurologic symptoms, and PCR testing at the time of neurological manifestations of both suspected and confirmed cases of COVID-19

Figure 2

Table 2: Demographics, clinical features, and GBS classification in patients with confirmed cases of COVID-19